Synth-Med Biotechnology
Synth-Med Biotechnology is dedicated to revolutionizing drug delivery systems through innovative technologies such as smart blood and erythrocyte-based therapeutics. Their mission is to develop precise, biocompatible delivery vehicles to treat neurological diseases, cancer, and other health conditions, aiming to save lives and improve patient outcomes. The company collaborates with leading institutions and has received recognition for its groundbreaking work in medical technology.
Industries
Nr. of Employees
small (1-50)
Synth-Med Biotechnology
MaRS Centre, West Tower, 661 University Avenue, Suite 1300, Toronto, Ontario, Canada M5G 0B7
Products
Erythrocyte-derived drug delivery platform
A modular delivery platform that transforms red blood cells into nano-carriers for targeted delivery of proteins, small molecules, peptides, and nucleic acids with reported applications in neuroscience and oncology.
Erythrocyte-derived drug delivery platform
A modular delivery platform that transforms red blood cells into nano-carriers for targeted delivery of proteins, small molecules, peptides, and nucleic acids with reported applications in neuroscience and oncology.
Services
Preclinical efficacy testing in animal models and computational/experimental optimization of erythrocyte-derived delivery systems.
Preclinical efficacy testing in animal models and computational/experimental optimization of erythrocyte-derived delivery systems.
Expertise Areas
- Erythrocyte-based drug delivery
- Blood–brain barrier delivery
- Oncology therapeutic delivery
- Membrane and lipid engineering
Key Technologies
- Erythrocyte-derived carriers
- Cell membrane engineering
- Hybrid erythrocyte liposomes
- Nanomanipulation of membranes
News & Updates
Synth-Med Biotechnology Inc. is proud to be selected for this year’s Creative Destruction Lab Advanced Therapies cohort. They are excited to join this community of innovators and collaborate on groundbreaking advancements in therapeutic technologies.
Synth-Med supported the Alzheimer’s Society at the Oxford Half 2024. They are committed to making a difference with their groundbreaking smart blood technology, which is being used to develop treatments for Alzheimer’s and dementia.
Synth-Med was featured in Hong Kong News in October 2024, highlighting their innovative work in medical technology.
Synth-Med is focused on transforming drug delivery with their proprietary computer-guided process that turns red blood cells into nano-carriers for precise drug delivery.
Synth-Med Biotechnology Inc. is proud to be selected for this year’s Creative Destruction Lab Advanced Therapies cohort. They are excited to join this community of innovators and collaborate on groundbreaking advancements in therapeutic technologies.
Synth-Med supported the Alzheimer’s Society at the Oxford Half 2024. They are committed to making a difference with their groundbreaking smart blood technology, which is being used to develop treatments for Alzheimer’s and dementia.
Synth-Med was featured in Hong Kong News in October 2024, highlighting their innovative work in medical technology.
Synth-Med is focused on transforming drug delivery with their proprietary computer-guided process that turns red blood cells into nano-carriers for precise drug delivery.